Attached files
| file | filename |
|---|---|
| EX-31 - EXHIBIT 31 - NEUROONE MEDICAL TECHNOLOGIES Corp | v472986_ex31.htm |
| 10-Q - 10-Q - NEUROONE MEDICAL TECHNOLOGIES Corp | v472986_10q.htm |
Exhibit 32
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of NeuroOne Medical Technologies Corporation. (the “Company”) on Form 10-Q for the quarter ended June 30, 2017 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Dave Rosa, Chief Executive Officer and Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
Date: August 14, 2017
| /s/ Dave Rosa | |
| Dave Rosa | |
| Chief Executive Officer | |
| (Principal Executive Officer) | |
| (Principal Financial Officer) |